Most material SEC filings — October 29, 2026

Maplebear Inc. (Instacart) entered a definitive acquisition agreement with DoorDash Inc. valued at approximately $17 billion in equity value, comprising cash and stock. Q3 2026 results showed GTV growth of 15% YoY to $10.5B, total revenue up 17% YoY to $1.1B, GAAP net income of $147M, and Adjusted EBITDA of $342M (up 23% YoY). The company has cancelled its earnings call and suspended forward guidance pending merger close.

On October 15, 2026, CCC announced a definitive agreement to be acquired by GTCR and Elliott Investment Management in an all-cash transaction at $7.75 per share, representing an enterprise value of approximately $6.1 billion. The transaction is expected to close in Q1 2027, subject to regulatory and stockholder approvals. Q3 2026 results showed revenue growth of 10.1% to $294.1M, adjusted EBITDA margin of 44%, and AI-related revenue of ~$130M at annualized run-rate (up 40% YoY).

RXO agreed to be acquired by C.H. Robinson in a stock-and-cash deal valued at $5.8 billion, expected to close H1 2027 pending regulatory and shareholder approval. Q3 2026 results exceeded profit outlook: revenue $1.9B (+32% YoY), adjusted EBITDA $51M (+59% YoY), adjusted EPS $0.09 vs. $0.01 YoY. Brokerage truckload volume grew 3% YoY with spot mix reaching 51% (vs. 29% prior year); Managed Transportation awarded ~$140M freight under management; Last Mile stops up 5% YoY.

On October 28, 2026, New ERA Energy & Digital (NUAI, ~$12M market cap) entered into a Securities Purchase Agreement to issue 23,272,727 shares at $2.75/share for approximately $64 million gross proceeds. The financing closed October 30, 2026. Purchasers include Brookdale Global Opportunity Fund, Davidson Kempner Arbitrage LP, M.H. Davidson Co., Hood River Small Cap Growth Fund, Alto Opportunity Master Fund, and Ghisallo Master Fund. Proceeds will repay Macquarie facility borrowings, fund working capital, and general corporate purposes. Company granted registration rights for resale of the shares.

Indivior reported Q3 2026 total net revenue of $356M (up 13% YoY) and SUBLOCADE revenue of $267M (up 22% YoY), with record net income of $137M and adjusted EBITDA of $211M (up 76% YoY). The company completed shareholder approval for its all-stock merger of equals with Supernus Pharmaceuticals, expected to close November 2, 2026; the combined entity will operate as Supernus under ticker SUPN. Indivior declared a special contingent cash dividend contingent on merger closing and ended Q3 with $332M in cash and investments.

LiveWire Group (LVWR, ~$105M market cap) reported Q3 2026 revenue of $7.9M (38% YoY growth) and unit sales up 21% to 7,233 units, driven by Electric Motorcycle (+178% revenue, +31% units) and STACYC segments (+9% revenue, +20% units). However, the company posted a $18.6M net loss for Q3 and $54.9M YTD loss; cash declined from $82.8M (Dec 2025) to $39.9M (Sept 2026). Management disclosed substantial doubt about going concern due to recurring operating losses, negative operating cash flows ($38.3M YTD, though 16% improved), and debt maturity in December 2027. On Oct 22, 2026, the Board formed a Special Restructuring Committee and appointed Roy Gallagher as Chief Restructuring Officer to pursue financing, partnerships, sales, or restructuring. The company withdrew full-year 2026 guidance of $70–80M operating loss.

DoorDash announced a definitive agreement to acquire Instacart for $65.00 per share (approximately $17 billion equity value), with consideration at least 75% cash and up to 25% DoorDash stock, subject to proration. The transaction is expected to close end-2027 or H1 2028, pending regulatory approvals and Instacart shareholder vote; ~19% of Instacart shares already committed to vote yes. DoorDash simultaneously reported Q3 2026 strong results: revenue $4.6B (+34% YoY), Marketplace GOV $33.9B (+36% YoY), net income $466M (+91% YoY), and Adjusted EBITDA $1,060M (+41% YoY).

BCB Bancorp reported a net loss of $132.5 million for Q3 2026 (vs. $3.8M profit in Q3 2025) driven by a $115.0 million provision for credit losses and a $59.9 million valuation allowance on deferred tax assets. The company completed a $98.0 million equity offering (net $91.4M) and sold $204.3 million of criticized/classified loans while transferring $100.9 million to held-for-sale status. Non-accrual loans declined to $22.4 million from $61.2 million at Q2 2026. Diluted EPS fell to ($6.92) from ($0.85) sequentially. The company added two independent directors and reorganized the C-Suite.

WESCO reported third-quarter 2026 net sales of $7.226 billion, up 16.6% reported and 16.6% organic YoY, with data center sales up ~55% to $1.8B. Adjusted EBITDA reached record $561.5M (7.8% margin, +100 bps YoY); adjusted diluted EPS hit record $5.77, up 47% YoY. Backlog surged ~80% YoY to record levels across all three business units (CSS, EES, UBS). The company raised full-year 2026 guidance: organic sales growth to 13–14% (from 9–11%), adjusted EBITDA margin to ~7.2% (from 6.9–7.1%), and adjusted EPS to $18.00–$18.50 (from $16.00–$17.50). Leverage improved to 2.8x from 3.4x at year-end 2025.

A.O. Smith announced definitive agreements on October 27, 2026, to sell an 81% stake in its China business to CPE (a leading alternative asset manager) for approximately $400M on a cash-free, debt-free basis. The deal includes total value exceeding $500M when accounting for long-term brand licensing royalties over decades. A.O. Smith retains a 19% stake, enters a long-term brand license agreement, and will repatriate ~$80M in cash held in China. Transaction expected to close H1 2027; proceeds will prioritize share repurchases.

Quanta reported Q3 2026 revenues of $12.01B (vs. $7.63B in Q3 2025), GAAP diluted EPS of $4.55 (vs. $2.24), and adjusted diluted EPS of $6.06 (vs. $3.33). Record backlog reached $63.7B. The company significantly raised full-year 2026 guidance: revenues now $41.3–$41.6B (prior guidance not stated), adjusted diluted EPS $17.90–$18.30. Completed two acquisitions for ~$245M aggregate consideration ($96M cash, $149M stock) in September-October 2026. Issued $2.0B senior notes in August 2026 and prepaid $618.8M term loan in September.

First Mid Bancshares, Inc. (parent company, ~$899.3M market value) agreed to acquire Evergreen Bancshares, Inc. (target) for fixed cash consideration of $5.20 per share plus 0.4081 shares of First Mid common stock per share. The merger agreement, dated October 28, 2026, involves a two-step process: Evergreen merges into First Mid's subsidiary Raven Sub LLC, then Raven Sub merges into First Mid. Evergreen shareholders approved the deal via voting agreements; transaction subject to regulatory approvals and customary closing conditions, with target closing by August 31, 2027.

Tradeweb announced a definitive agreement to acquire Trumid Holdings, LLC for approximately $1.97 billion ($1.89 billion cash, $82 million equity), comprising $1.75 billion for the business and $220 million for tax assets (NPV ~$345 million). The acquisition is expected to close in H1 2027. In Q3 2026, Tradeweb reported $584.5 million in revenues (up 14.9% YoY), $3.2 trillion average daily volume (up 22.4% YoY), adjusted EBITDA of $318.9 million (up 16.2% YoY), and adjusted diluted EPS of $1.02 (up 17.2% YoY). The company increased its quarterly dividend 16.7% to $0.14/share and repurchased 2.02 million shares for $209.8 million.

Pagaya reported Q3 2026 GAAP net income of $50M (+121% YoY), total revenue $390M (+12% YoY), network volume $3.6B (+29% YoY), and adjusted EBITDA $130M (+22% YoY). The company onboarded Citizens Financial Group and First National Bank of Omaha, bringing total new partners to 6 in the past 12 months. Pagaya raised full-year 2026 GAAP net income guidance to $162M–$182M (previously unspecified) and closed >$2B in committed capital across three funding structures. FRLPC % contracted 91 bps YoY to 4.1% due to higher benchmark rates, partially offset by 100–140 bps APR increases implemented in September.

LKQ Corporation reported Q3 2026 revenue of $3.3 billion, down 5.1% YoY ($180M decline), with net loss of $24 million versus net income of $178 million in Q3 2025. The company posted $111 million in impairment charges (goodwill $88M, assets held for sale $23M). Diluted EPS fell to -$0.09 from +$0.69. The Board appointed Salvatore Abbate as new CEO (effective December 15, 2026), engaged turnaround consultant Alvarez & Marsal, suspended the Specialty segment sale process, withdrew full-year 2026 guidance, and cited operational issues in Europe (ERP implementation in Germany, UK/Benelux declines) and weakness in Specialty as key drivers. Total debt is $3.7 billion (2.8x leverage).

Cheniere Partners raised full-year 2026 distribution guidance to $3.30–$3.40/unit (from $3.10–$3.40), backed by strong Q3 results: $2.6B revenue, $0.6B net income, $1.0B Adjusted EBITDA. In October 2026, subsidiary Sabine Pass Liquefaction signed a long-term SPA with QatarEnergy to supply up to 2 mtpa LNG annually (early 2030s–2054), with 1 mtpa contingent on positive FID for SPL Expansion phase one. September 2026 FERC issued final environmental statement for expansion; term loan commitments secured (~50% of phase-one costs, closing subject to FID).

ATI reported Q3 2026 sales of $1.42B (+26% YoY) with net income of $190M (+73% YoY) and adjusted EBITDA of $328M (+46% YoY). The company raised full-year 2026 adjusted EBITDA guidance by $35M to $1.19–$1.20B (following a $125M raise last quarter) and adjusted EPS guidance to $5.17–$5.23. Growth driven by commercial jet engine demand, aerospace & defense strength (69% of sales), and margin expansion to 23.0%. Cash from operations was $415M YTD; company repurchased $70M of stock in Q3.

On October 27, 2026, INmune Bio (a $51M market-cap company) sold 3,000,000 common shares at $1.50/share for $4.5M aggregate proceeds, plus issued warrants to purchase 3,000,000 additional shares at $1.65 exercise price, 100% warrant coverage. Warrants exercisable from April 27, 2027 through April 27, 2032. Shares sold registered under Form S-3; warrants/warrant shares issued under Rule 506(d) exemption. No specific purchaser counterparty named in agreement template.

Valion Bio announced positive safety results from a National Institute of Allergy and Infectious Diseases (NIAID)/Radiation and Nuclear Countermeasures Program-funded study conducted by the Armed Forces Radiobiology Research Institute (AFRRI) on Entolimod, its lead biologic candidate for acute radiation syndrome. A single subcutaneous injection of Entolimod at 0.72 mg/kg in 20 male C57BL/6 mice demonstrated no treatment-related toxicity, with stable body weight, unchanged hematologic profiles, and normal organ/metabolic function across all measured parameters over a 14-day observation period. The positive safety data de-risks the program and enables advancement to a fully government-funded therapeutic efficacy study focusing on survival and gastrointestinal recovery following radiation exposure.

Xerox reported Q3 2026 revenue of $1.868B (down 4.7% YoY) and GAAP net loss of $1.015B ($7.73/share), including a $959M non-cash goodwill impairment charge related to the Print and Other segment. The company lowered full-year 2026 adjusted operating income guidance to $450–$475M (from $555–$605M) and free cash flow guidance to $50–$100M (from $250M), citing higher input costs, market headwinds, and macro uncertainty. Management suspended common and preferred dividends effective immediately and exchanged $174M of 5.50% 2028 Senior Notes for $121M of 10.25% 2030 Senior Secured Notes plus $9M equity.

Proto Labs reported Q3 2026 revenue of $154.3M (+14.0% YoY), record quarterly result with GAAP EPS of $0.48 (+61% YoY) and non-GAAP EPS of $0.63 (+33% YoY). Company raised full-year 2026 revenue growth guidance from 8-10% to 10-11%. Broad-based growth across all product lines: CNC machining +16.4%, injection molding +12.5%, 3D printing +11.4%; operating margins expanded to 9.4% GAAP and 11.9% non-GAAP.

Granite Construction reported Q3 2026 revenue of $1.77B (+23% YoY), adjusted net income of $173M (+39% YoY), and adjusted EBITDA of $283M (+32% YoY). Record Committed and Awarded Projects (CAP) reached $7.5B (+$1.1B YoY). The company settled 3.75% convertible notes primarily in cash (~$162M net charge in Q3), reducing share dilution. Management introduced 2029 targets: organic revenue CAGR 10-12%, adjusted EBITDA margin 14-16%, and 2.5x net leverage target. 2026 revenue guidance raised to $5.4-5.5B (from $5.3-5.5B).

TechnipFMC reported Q3 2026 revenue of $2.9B (9.4% YoY growth) with net income of $418.4M ($1.05 diluted EPS). Subsea inbound orders totaled $2.1B in Q3; company raised full-year 2026 Subsea revenue guidance to $9.6–$9.8B (from $9.2–$9.6B) and free cash flow to $1.45–$1.55B (from $1.3–$1.45B). Management forecasts at least $14.5B in Subsea orders over next five quarters (through 2027) and initiated 2027 Subsea guidance of $10.0–$10.4B revenue and 22.5–24.0% adjusted EBITDA margin. Key wins: Azule Energy (Angola), Petrobras (Brazil), PETRONAS (Malaysia iEPCI), plus strategic partnerships with bp (Gulf of America) and PETRONAS.

First Mid Bancshares (FMBH, ~$899M market cap) announced a pending acquisition of Evergreen Bancshares, Inc. (holding American Bank of Freedom) with ~$932M assets, ~$727M deposits, and 10 branches in St. Louis/Indianapolis markets. Q3 2026: net income $33.3M ($1.25 diluted EPS, record quarterly), deposits up $44.2M to $7.62B, loans down $85.8M to $6.85B. Also agreed to acquire Winship Farm Management (8,600+ acres over 3 years). Evergreen deal priced at 1.10x tangible book value; pro forma 2028E ~5% EPS accretion (7% ex-Durbin), minimal 0.5% TBV dilution at close with 0.5-year earnback. No financial terms disclosed for Winship.

Monro reported Q2 FY2027 sales of $283.6M (down 1.8% YoY) and net loss of $1.6M vs. net income of $5.7M prior year. On October 23, 2026, the company entered into new senior secured credit facilities with Ares Capital Corporation: $250M term loan + $125M revolver (total $375M), maturing October 23, 2030, replacing prior facility since April 2019. Operating income collapsed to $2.6M (0.9% margin) from $12.8M (4.4% margin); adjusted operating income fell to $4.4M (1.6%) from $14.0M (4.8%). As of October 24, 2026, cash was $27.3M with $60M available under new facilities.

Belden Inc. reported Q3 2026 revenues of $966M (up 38% YoY, 11% organic), record orders of $1,017M, and adjusted EPS of $2.26 (+15% YoY). The company signed a binding agreement to supply $100M of fiber solutions to a major US data center customer in 2027, projected to drive >50% data center business growth. GAAP EPS was negative $0.29 due to $100M in non-cash purchase accounting charges related to the Ruckus acquisition.

Builders FirstSource reported Q3 2026 net sales of $3.9B (down 2.2% YoY), with gross margin declining 260 bps to 27.8% due to lower housing starts. Net income fell 50.6% to $60.4M ($0.56 diluted EPS vs. $1.10 prior year); Adjusted EBITDA dropped 28.3% to $311.1M. Free cash flow plummeted 83.7% to $76.0M from $464.9M. Net debt/LTM EBITDA rose to 4.1x from 2.3x. Company narrowed 2026 full-year guidance range but maintained midpoints: $14.2–14.6B net sales, $1.075–1.125B Adjusted EBITDA.

L3Harris reported Q3 2026 revenue of $6.1B (+7% YoY), orders of $19.3B (record backlog $53.2B, 3.2x book-to-bill), and diluted EPS of $3.28 (+33% YoY). The company raised full-year 2026 revenue guidance floor from $23.2B to $23.5B and raised GAAP EPS guidance from $11.80–$12.00 to $12.25–$12.35. Major wins include $6.3B THAAD propulsion contract and $4.7B PAC-3 MSE contract. Operating cash flow was $1.4B; free cash flow $1.3B (+195% YoY). Total debt $11.0B; net debt leverage 1.9x.

Brunswick reported Q3 2026 net sales of $1,453.9M (+7% YoY) with adjusted diluted EPS of $1.58 (+63% YoY). The company raised full-year 2026 adjusted EPS guidance to ~$4.65 (from prior undisclosed level), net sales to $5.7–5.8B, adjusted operating margin to ~8.0%, and free cash flow to $400M+. All four segments grew sales YoY for the fifth consecutive quarter; Propulsion margin expanded 350 bps, Boat segment earnings doubled. CEO David Foulkes will be succeeded by Aine Denari effective January 1, 2027.

Butterfly delivered Q3 2026 revenue of $32.6M (52% YoY growth), beating guidance with 73% gross margin—highest in company history. Adjusted EBITDA loss improved 85% to -$1.2M vs. -$8.1M YoY. Management raised FY2026 revenue guidance to $123–$126M (26–29% growth) and adjusted EBITDA loss guidance to -$12M to -$15M. Key drivers: Embedded partnership revenue (Mendaera launched Oct 1; 3 new BCI partners added), five 7-figure enterprise deals, FedRAMP authorization, and Home & Community Care launch beginning November with initial Q4 revenue expected.

XPO reported Q3 2026 revenue of $2.373B (+12.4% YoY) and diluted EPS of $1.53 (+125% YoY); adjusted diluted EPS was $1.70 (+58.9% YoY). North American LTL segment drove growth with revenue of $1.473B (+17.4%) and adjusted operating income of $293M (+35.0%); adjusted operating ratio improved 260 basis points to 80.1%. European Transportation revenue grew 5.0% to $900M with adjusted EBITDA of $48M (+26.3%). Nine-month YTD adjusted EBITDA was $1.186B (+23.5%), and the company returned $250M to shareholders via stock repurchases.

Tenet reported Q3 2026 net income of $1.0B ($12.41/diluted share) vs. $342M ($3.86) in Q3 2025, and adjusted diluted EPS of $6.64 vs. $3.70. Q3 Adjusted EBITDA rose 23.3% to $1.355B. Company raised FY 2026 Adjusted EBITDA guidance midpoint by $195M to $5.05–$5.20B and Adjusted Free Cash Flow by $100M to $2.825–$3.125B. Key driver: $233M revenue catch-up and $50M transition benefit from accelerated Conifer RCM contract wind-down with CommonSpirit Health (completing by Dec 31, 2026). Also repurchased 7.99M shares for $1.615B YTD and refinanced $2.0B new senior notes in Sept 2026.

NovoCure reported Q3 2026 net revenue of $193.4M (16% YoY growth) driven by 19% active patient growth to 5,260 globally. The company raised full-year 2026 guidance to $736M–$743M revenue (prior: $710M–$725M) and $24M–$34M adjusted EBITDA (prior: $0M–$15M). Key driver: Optune Gio remains core (4,729 patients); newer products Optune Lua (255 patients, +83% YoY) and Optune Pax (276 patients, newly launched) contributed $11.9M combined quarterly revenue. Japan approved Optune Pax in October 2026. Adjusted EBITDA swung to $15.7M positive (Q3 2025: -$3.0M). However, net loss was $10.4M (Q3 2025: -$37.3M loss), and company remains unprofitable YTD.

Bandwidth reported Q3 2026 revenue of $234M (+22% YoY) and Adjusted EBITDA of $35M (+43% YoY) with 22% margin. Nine-month 2026 revenue reached $663M (+21% YoY) with $89M Adjusted EBITDA (+31% YoY). Full-year 2026 guidance: $905–910M revenue and $124–125M Adjusted EBITDA. Four new $1M+ customer wins added, including a digital banking platform, privacy company, enterprise network provider, and international carrier expansion; Salesforce named Bandwidth first certified international carrier for global Contact Center rollout across 25+ countries.

Crocs reported Q3 2026 revenue of $1,043M (+4.6% YoY), with Crocs Brand up 4.4% and HEYDUDE returning to growth at +6.1%. The company repurchased 2.0M shares for $250M and raised full-year revenue guidance to ~3% growth (from 1-2%), full-year adjusted EPS to $14.45–$14.65 (from $13.70–$14.00), and full-year adjusted operating margin guidance modestly upward from 22.3% to 22.5%. This marks the third consecutive FY26 guidance raise.

HGV reported Q3 2026 contract sales of $807M (down 11% YoY), with diluted EPS of $3.70 (vs. $0.28 prior year), boosted by $296M net construction recognition from Hawaii project completion. The company cut FY 2026 Adjusted EBITDA guidance from $1.225-1.265B to $1.165-1.180B, citing slower-than-expected ramp of summer sales initiatives. Key metrics: VPG declined 12.5%, tour flow up 1.7%; liquidity of $684M (cash plus revolving capacity); net leverage 3.9x; share repurchases of 2.4M shares for $110M in Q3.

Phathom Pharmaceuticals reported Q3 2026 net revenues of $84.7 million (up 71% vs. Q3 2025, up 14% vs. Q2 2026), driven by continued VOQUEZNA commercialization reaching 2 million total prescriptions filled through October 16, 2026. The company achieved positive operating cash flow for the second consecutive quarter, generated non-GAAP adjusted net income of $3.0 million (vs. adjusted net loss of $11.2 million in Q3 2025), and maintained full-year 2026 guidance of $310–325 million net revenue. Cash position as of September 30, 2026 was $184.6 million, with the company facing litigation risk from BDR Pharmaceuticals challenging VOQUEZNA's 10-year NCE exclusivity (through May 3, 2032), though the company expects Q4 2026 topline results from its Phase 2 EoE trial and initiated a Phase 3 as-needed use study (pHalcon-NERD-302) with topline results expected Q1 2028.

The Clorox Company announced that its Board has appointed Fabian Garcia as CEO, effective January 5, 2027, succeeding Linda Rendle who steps down for health reasons. Garcia, currently president of Unilever Personal Care with 40+ years of consumer products experience (prior roles: CEO of Revlon, COO at Colgate-Palmolive, executive at Procter & Gamble), will join the Board. Matthew Shattock will become independent chair; Rendle will serve in advisory capacity through April 2, 2027.

West Pharmaceutical reported Q3 2026 net sales of $874.5M (8.7% reported, 11.9% organic growth). The company raised full-year 2026 net sales guidance to $3.41–$3.42B (from $3.345–$3.380B) and adjusted-diluted EPS guidance to $9.38–$9.48 (from $8.85–$9.05). High-Value Product (HVP) Components drove growth at 20.3% organic, representing 53% of total sales. The company completed the divestiture of SmartDose 3.5mL to AbbVie, recording a $55.7M gain. Capital expenditures were reduced to $215–$220M guidance from prior $250–$275M. Share repurchases totaled $685M year-to-date.

For Q2 FY2027 (ended Sept 25, 2026), Allegro reported net sales of $276.9M (up 29% YoY from $214.3M), with Automotive sales of $172.5M (+11% YoY) and Industrial/Other of $104.4M (+79% YoY). GAAP diluted EPS quadrupled to $0.12 vs $0.03 YoY; non-GAAP diluted EPS doubled to $0.26 vs $0.13. The company posted GAAP operating income of $35.4M (12.8% margin) vs $6.2M (2.9% margin) YoY. On Sept 30, 2026, Allegro made a $25M voluntary debt repayment. For Q3 FY2027 guidance, the company projects sales of $278–288M (23% YoY growth at midpoint) and non-GAAP diluted EPS of $0.25–$0.29.

Kymera reported positive Phase 1 healthy volunteer data for KT-579 (IRF5 degrader) showing ≥90% median IRF5 degradation, robust biomarker suppression (88-98% inhibition of inflammatory cytokines), and favorable safety profile comparable to placebo. KT-621 (STAT6 degrader) BROADEN2 Phase 2b atopic dermatitis trial completed enrollment in October 2026 with topline data expected by year-end 2026; Phase 3 AD trial planned for mid-2027. Company has $1.6B cash with runway into 2029. Q3 2026 net loss was $132.0M vs. $82.2M in Q3 2025; R&D expenses increased to $128.5M (from $74.1M year-over-year) driven by STAT6 program expansion.

Stagwell reported Q3 2026 net revenue of $664M (+8% YoY), adjusted EBITDA of $145M (+25% YoY), and adjusted EPS of $0.34 (+42% YoY). The company raised full-year 2026 adjusted EBITDA guidance to $490M–$540M (from prior guidance) and adjusted EPS to $1.07–$1.21, while reiterating 8–12% total net revenue growth. Key drivers: Digital Transformation organic net revenue growth of 23%, The Marketing Cloud organic growth of 108%, $168M in Q3 net new business (LTM $586M), and $59M of enterprise technology contracted revenue YTD, exceeding the initial $25M 2026 goal. Net leverage improved to 2.7x, and operating cash flow increased 396% YTD to $152M. Counterparties mentioned: ServiceNow (largest multi-agency deal), U.S. Central Command (first major federal win), and Palantir (expanded partnership).

Leonardo DRS reported Q3 2026 revenue of $1.1B (+11% YoY) and net earnings of $115M (+60% YoY), with diluted EPS of $0.43 (+65% YoY). The company raised 2026 full-year guidance: revenue to $3.95–$3.985B (from $3.9–$3.975B), Adjusted EBITDA to $545–$555M (from $525–$540M), and Adjusted Diluted EPS to $1.50–$1.53 (from $1.34–$1.39). Record funded backlog reached $5.6B (+21% YoY), with bookings of $1.6B and 1.5x book-to-bill ratio. The company declared a $0.09/share quarterly dividend and repurchased 288,633 shares for ~$12M in Q3; cash position stood at $294M with no debt outstanding.

CRH completed acquisition of Arcosa Inc. for $8.5B ($150/share cash) on October 23, 2026, financed via $2.5B term loan, $3.3B bridge facility, and cash on hand. Simultaneously launched Velocity, a transformation initiative targeting $400M annual run-rate benefits by end of 2028 with ~$400M total implementation costs ($49M incurred through Q3). Also announced new $6B share buyback program expiring end of 2030 and revised 2026 full-year guidance downward: net income $3.1B–$3.3B (prior $3.9B–$4.1B) and Adjusted EBITDA $7.8B–$8.0B (prior $8.1B–$8.5B).

Acadian Asset Management reported Q3 2026 results with AUM of $239.6B (up 44% YoY), record quarterly management fees of $187.8M (up 38% YoY), net inflows of $2.6B (4% annualized organic growth), U.S. GAAP net income of $35.5M (up 135% YoY), and ENI EPS of $1.36 (up 79% YoY). The company declared a $0.10/share quarterly dividend payable December 23, 2026. Operating margins expanded 940 basis points to 42.6% ENI operating margin, driven by management fee revenue growth exceeding operating expense growth, with leverage ratios declining to 0.7x debt/EBITDA and 0.2x net leverage.

Oshkosh reported Q3 2026 diluted EPS of $2.22 (down 27% YoY from $3.04) on sales of $2.84B (+5.7% YoY). The company lowered full-year 2026 adjusted EPS guidance to $8.50–$9.50 (down $1.50–$2.50 from prior guidance) and net sales to ~$11.0B (down $0.2B), citing fire truck production challenges tied to manufacturing transformation. Vocational segment operating income fell 38% to $87.6M as fire apparatus output declined. Access segment grew 20.7% in sales with margin expansion. The company repurchased 556,138 shares for $82.4M and maintained its $0.57 quarterly dividend.